Navigation Links
Vaccine extends glioblastoma patients' survival in phase II trial

HOUSTON - A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

Eighteen newly diagnosed patients who were vaccinated after undergoing standard treatment - surgery followed by radiation and chemotherapy - had median overall survival of 26 months compared with 15 months for 17 patients in a control group who received standard treatment. Median survival for newly diagnosed patients with glioblastoma multiforme is 14.6 months.

Vaccinated patients also experienced a longer period before their disease progressed, 14.2 months, compared with 6.3 months for the control group. Side effects were limited mainly to irritation at the injection site.

"This promising targeted therapy blocks a key molecular signal that drives the malignant features of these tumors," said Amy Heimberger, M.D., associate professor in MD Anderson's Department of Neurosurgery and co-lead author of the paper. "If a patient's tumor expresses the target of this vaccine, she usually has only a 5 percent chance to live for two years."

All patients in the trial had the target variation, called epidermal growth factor receptor variant III (EGFRvIII), which occurs in about a third of glioblastomas and also is found in breast, lung and head and neck cancers. The flawed gene produces a protein that aids tumor development, migration and resistance to chemotherapy and radiation. It is not found in normal tissue.

Out of 11 tumor recurrences analyzed from vaccinated patients, the EGFRvIII cells were completely gone in nine, indicating that the vaccine had done its job eliminating the most aggressive cells, said co-lead author John Sampson, M.D., Ph.D., professor of Neurosurgery at Duke.

Other findings hint at the vaccine's likely effectiveness against EGFRvIII. Of six patients who had an immune response to the vaccine as indicated by blood tests, overall survival was 47.7 months compared with 22.8 months for those lacking a response. Median survival had not been reached after 50 months among three patients who had a T cell response to the vaccine.

However, the limited size of the sample calls for cautious interpretation of these results, Heimberger said. The next step for the vaccine, known as CDX-110, is a large phase III clinical trial, Heimberger said, which is in the planning stage.

The EGFRvIII variant was co-discovered by Bert Vogelstein, M.D., and Albert Wong, M.D., at Johns Hopkins University and Darrell Bigner, M.D., Ph.D., director of the brain tumor center at Duke and corresponding author of the JCO paper.

Glioblastomas have other molecular drivers, so tumors come back, which the authors say points to a need to develop vaccines that address more than one target.

Heimberger sees the addition of vaccines to glioblastoma treatment as one more way to convert the deadly tumors more of a chronic disease. Developments in recent years, including approval of the chemotherapy drug temozolomide, have extended expected survival from around seven months to 14.


Contact: Scott Merville
University of Texas M. D. Anderson Cancer Center

Related medicine news :

1. Vaccine May Prevent TB in People With HIV
2. Vaccine Not Fail-Safe in Ongoing Mumps Outbreak
3. New strategy produces promising advance in cancer vaccines
4. Screens, Vaccine for HPV Less Beneficial in Older Women
5. New Technology Could Widen Reach of Vaccines
6. Texas-based consortium announces groundbreaking vaccine research program
7. The Coalition for Vaccine Safety Calls for Congressional Hearings on Federal Agencies Failure to Provide Adequate Safety Research
8. Possible vaccine for mesothelioma proven safe
9. Groundbreaking research to find vaccine for hepatitis C
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. CDC Awards Abt Associates Additional Contracts to Evaluate Effectiveness of H1N1 Vaccine
Post Your Comments:
Related Image:
Vaccine extends glioblastoma patients' survival in phase II trial
(Date:11/30/2015)... ... November 30, 2015 , ... ... announce the speakers for “Value-Based Payer-Provider Partnerships: Three Case Studies,” an upcoming ... value-based care arrangements: Essentia Health and UCare, MissionPoint Health Partners, and Intel ...
(Date:11/30/2015)... ... November 30, 2015 , ... Insightra ... TIGR® Matrix Surgical Mesh technology for soft tissue repair in the US via ... a long-term resorbable surgical mesh intended to support and reinforce soft tissue for ...
(Date:11/30/2015)... ... , ... GKhair & Tibolli team members and artists were excited and proud ... 8th and 9th at the Puerto Rico Convention Center, San Juan Puerto Rico. The ... of the line fashion journalists. The San Juan Beauty Show carries immense credibility among ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... to announce their strategic partnership at the Radiological Society of North America ... and Winscribe, global providers of cutting-edge dictation and speech-enabled documentation software, announced ...
(Date:11/30/2015)... Miami, FL (PRWEB) , ... November 30, 2015 ... ... manufacturer and engineer of patented products, announces the Unstoppable Swappables, a household invention ... Window Coverings Industry makes $2 billion a year and is growing at 2.6%," ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 Elbit Imaging ... "Company") announced today that it was informed by InSightec Ltd. ... Safety (MFDS) has approved its Exablate Neuro system to ... --> --> Insightec,s Exablate Neuro platform ... that combines two technologies: Focused Ultrasound, which is used ...
(Date:11/29/2015)... Nov. 29, 2015  The GE Health Cloud 1 ... Society of North America (RSNA) meeting ... healthcare industry, the new cloud ecosystem and its applications will ... care pathways and multidisciplinary teams – both inside and outside ... and CEO of GE. "As the digital industrial leader, we ...
(Date:11/27/2015)... Niederlande, November 27, 2015 ... bei fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   --> Ein ... fortgeschrittenem Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November ...
Breaking Medicine Technology: